A BSTRA CT To determine whether digoxin-specific antibodies can reverse established digoxin toxicity in the dog, digoxin intoxication was produced by the intramuscular administration of digoxin, 0.09 mg/kg, on each of 3 consecutive days. All animals developed toxic arrhythmias (atrioventricular block, ventricular premature contractions and/or ventricular tachycardia). In control animals not receiving antidigoxin antibodies, the arrhythmias persisted throughout a 6 hr study period. Seven of the nine control dogs were dead within 24 hr and one moribund animal was sacrificed at that time; the last animal died within 48 hr.
INTRODUCTION
Digitalis intoxication is a serious and frequently encountered clinical condition. Since no specific antagonist of digitalis has yet been described, present-day therapy is directed principally at the symptomatic management of the clinical manifestations of digitalis toxicity (2) rather than at its cause. To provide a more direct approach, the present study was designed to determine whether antibodies which specifically bind cardiac glycosides can reverse established digitalis toxicity. The (5) .
This communication presents evidence that digoxinbinding antibodies are capable of reversing the toxic effects of excessive digoxin in the nonimmunized dog. The potential value of these antibodies in the clinical treatment of life-threatening human digoxin intoxication is discussed.
METHODS
Preparation of antigens. Digoxin' was conjugated to human serum albumin2 (HSA)' or to bovine serum albumin (BSA)' by the periodate oxidation method (3, 6 ) as previously described (7) .
Imnumization. White New Zealand rabbits were immunized with HSA-digoxin (HSA-Dig) or with BSA-digoxin (BSA-Dig) in complete Freund's adjuvant mixture as described in detail elsewhere (7) . Other rabbits were immunized in a similar manner with purin-6-oyl-HSA (Pur-HSA) (8) or with human y-globulin (HGG). 4 Mongrel dogs weighing from 10 to 20 kg, were immunized by the intramuscular injection of 1 ml of HSA-Dig in complete Freund's adjuvant mixture, once weekly for 4 wk, followed by monthly intramuscular booster injections.
Collection of antisera or plasma. Serum was obtained from the rabbits by cardiac puncture or via an ear vein. Some of the bleedings from individual rabbits were pooled. Thimerosal 5 in a final concentration of 1: 10,000 was added as a preservative and the sera were stored at 4VC until used.
Plasma was obtained from dogs 5-7 days after booster injections by plasmapheresis using the following technique: The dogs were anesthetized by the intravenous administration of sodium thiamylal 0 (5% solution in isotonic NaCl; 0.2 ml/lb). Blood was collected in a 250 ml plastic bag containing a citrate anticoagulant solution7 through a Teflon catheter' placed in the femoral artery via a cutaneous incision. The blood was then centrifuged at 1000 rpm at 40C for 20 min 9 or at 5000 rpm at 4VC for 3-5 min.' The plasma was then extruded" into a 150 ml plastic bag,'2 and then stored at 4VC until used. No preservative was added. The packed cells were reinfused into the dog through a Teflon catheter 8 in the vein of the foreleg. The removal of blood, separation of plasma, and readministration of cells were repeated for a total of 3 times so that approximately 450 ml of plasma was obtained per bleeding.
Determination of antibody concentration and digoxinbinding capacity. The presence of digoxin-binding antibodies was determined by the dextran-coated charcoal method (9, 10 (Table II) was calculated by multiplying the titer by 16 mgg (to obtain the theoretical digoxin-binding capacity of 1 ml of undiluted serum or plasma), and then multiplying by the total volume (in milliliters) infused.
The presence of antibodies to the protein antigens used in this study was determined by the bis-diazotized benzidine hemagglutination method, using human group "A" erythrocytes coated with HSA-Dig, BSA-Dig, Pur-HSA, or with HGG as previously described (4, 11) . Titers were recorded as the highest dilutions of sera which yielded an agglutination pattern of two-plus or greater (11 needle electrodes, a six lead electrocardiogram was recorded on photographic paper using paper speeds of 25 mm/sec and an additional recording was obtained at a paper speed of 75 mm/sec for the evaluation of rhythm. Arrhythmias appeared 1-3 hr after the 3rd dose of digoxin. When an arrhythmia had been present for 30 -60 min, a 6 hr study period was begun. During this 6 hr study period, the animal was kept suspended in the sling and rhythm strips were recorded every 15 min. All electrocardiograms were analyzed for heart rate, rhythm, P-R interval, and QRS duration.
Administration of serum or plasma. With the dog suspended in the standing position in the sling, varying amounts of canine plasma or rabbit serum were infused through a Nylon filter '4 and a Teflon catheter 8 over a 15-30 min period, starting 1-2 hr after the onset of digoxin toxicity. Some animals were given additional infusions at later times as indicated in Fig. 2 .
Determination of serum or plasma potassium concentration. The concentration of potassium in the canine plasma or rabbit serum infused was determined by means of a flame photometer.' RESULTS Digoxin toxicity. Electrocardiographic and gastrointestinal manifestations of digoxin intoxication appeared in all 17 dogs receiving the dose of digoxin employed in this study (0.09 mg/kg intramuscularly, once daily for 3 consecutive days). No toxic manifestations were noted after the first dose of digoxin, but all animals weighed less before the second and third injections of digoxin. Following the 2nd dose, transitory vomiting and diarrhea were noted in some animals but, prior to the third dose of digoxin, all were in normal sinus rhythm. Within 1 to 3 hr after the third dose, each dog had developed a sustained arrhythmia. These arrhythmias included: Atrioventricular dissociation with ectopic ventricular beats; atrioventricular dissociation with a junctional rhythm; various forms of atrioventricular block; slow idioventricular rhythm with no evidence of atrial activity; and ventricular tachycardia (Fig. 1 ) . The development of one of these arrhythmias was the criterion used for the presence of digoxin toxicity but, in addition to these arrhythmias, the animals displayed anorexia, protracted vomiting, diarrhea, weakness, and apathy.
Digoxin toxicity in untreated dogs and dogs receiving control serum or plasma. The course of digoxin toxicity in nine dogs, none of whom received digoxin-specific antibodies is summarized in Table I and is depicted in Fig. 2 . All nine dogs exhibited arrhythmias which persisted throughout the 6 hr study period. Normal sinus rhythm was not observed at any time (Fig. 2) . Seven of these dogs were dead within 24 hr and one moribund animal was sacrificed at this time. The arrhythmias and eventual lethal outcome in dogs 6 and 7 were not affected by the administration of normal canine plasma in two 130 ml portions (Fig. 2) . Dogs 8 and 9 each received, without apparent effect, 400 ml of rabbit serum containing antibodies to antigens unrelated to digoxin 1 hr after the onset of their arrhythmias (Fig. 2) . Dog 8 received serum containing antibodies to Pur-HSA and dog 9 received serum contraining antibodies specific for HGG. The rabbit sera contained antibodies to the corresponding antigens, but neither the canine l)lsnma nor the rabbit sera contained digoxin-binding antibodies (Table II) .
Effect of digoxin-specific antibodies on the course of digoxin toxicity. After digoxin-induced arrhythmias had been allowed to persist for 1 hr in eight animals (dogs 10 through 17), serum or plasma from animals immunized with digoxin-protein conjugates was administered intravenously in the amounts indicated in Table II . All such serum or plasma administered contained digoxin-binding antibodies (Table II) . Potassium concentrations tlid not differ significantly from the potassium concentrations of control serum or plasma (Table II) nor from the normal potassium concentrations of rabbit serum (12) . The reported potassium concentrations for heparinized canine plasma (13) are higher than those encountered in the present study (Table II) , but these lower concentrations may reflect dilution by citrated anticoagulant solution. In no instance did the total volume of antidigoxin serum or plasma administered exceed the maximum volume of serum or plasma (400 ml) given to control animals (Table II) .
The effect of these digoxin-specific antibodies on the arrhythmias in these animals is outlined in Table III and graphically represented in Fig. 2 . Dog 10 had atrioventricular dissociation which reverted to normal sinus rhythm within 1 hr after the administration of The horizontal axis represents the duration of the stu(dy period in hours after the onset of arrhythmia.
to di-oxin. All nine animals not treated \-ith digoxinsl)ecihlc antibtodies weele hn 48 hr of their last dose of digoxin (this number includes one moribuid dog sacrificed 24 hr after the last (lose of this (1rm-g) Tn contrast, six of the eight clogs given dcigoxinspecihc antibodies were in normal sinus rhythm at the en(l of 6 hr, and all eiolht were free of gastrointestinal and other clinical manifestations of d(igitalis intoxication at that time. All eight animals, moreover, were alive and in normal sinus rhythm at the end of 72 lr.
It can l)e concluded therefore that (ligoxin-sp)ecific antibodies can abolish toxic arrhvthimas, reverse clinical evidence of toxicity, and preve-nt death in clogs given a toxic close of (ligoxin.
The mechanism hw which a itidigoxini antibodlies reverse the toxic cellular effects of excessive miivocardial cliooxin has lnot beeni established in the current stu(lv. \We l)elieve, on the basis of earlier studies shoxinmg removal of cli-oxin from kidney cells and ervthrocvtes in vitro (5) , that this reversal may occur as tile result of a diminished myocardial concentration of digoxin, but direct evidence for this mechanism has not yet been obtained with myocardial cells. An alternative, but less likely, explanation is that antibody binds digoxin at a cell membrane or intracellular (14) site, thereby inactivating the glycoside. Hypokalemia (15) and hypomagnesemia 16) are known to predispose to the development of digitalis toxicity. Hence, consideration was given to the possibility that the reversal of toxicity might be due to correction of potassium or magnesium deficiency by antidigoxin serum or plasma. However, in five digoxin-intoxicated dogs, serum potassium and magnesium concentrations were within normal limits. Moreover, the concentrations of potassium in serum or plasma containing antidigoxin antibodies were normal or low in all instances and did not differ significantly from their concentrations in control serum or plasma administered to dogs 6-9 (Table II) . Thus, at present, there is no evidence that correction of potassium or magnesium deficits played any significant role in the reversal of digoxin toxicity by serum or plasma containing digoxin-specific antibodies.
Although reversal of digoxin toxicity and eventual restoration of normal sinus rhythm occurred in all eight animals receiving digoxin-specific antibodies, significant differences in their responses were observed. Some of these differences in response may have been related to the relative quantities of antibody administered. For example, the transitory effect of the first antibody infusion in dog 12 and the lack of effect after the first Persisting until the end of 6 hr study period. § Reverted to AV block with brief periods of ventricular tachycardia. II Transitory period or original arrhythmia occurred at times indicated in Fig. 1. antibody infusion in dog 13 are probably related to the relatively low digoxin-binding capacities of the canine antidigoxin plasma employed. In both instances, the subsequent administration of more potent rabbit antidigoxin serum was followed by a restoration of normal sinus rhythm (Table III) . However, not all of the observed differences in response can be ascribed to differences in the amount of antibody administered. For example, dog 10 reverted permanently to normal sinus rhythm after receiving enough antibody to bind 27% of the final dose of digoxin, but the initial response in dogs 14 and 15, both of which received more antibody, was transitory (Fig. 2 (Fig. 2, Table III) ; however, 2-3 days were required for the restoration of normal sinus rhythm in these instances.
The basis for these differences in electrocardiographic response to antidigoxin antibodies is not known at this time. The dogs employed in this study did differ markedly in their electrocardiographic response to the same toxic dosage of digoxin (Table I, III) . It is well known that many factors alter host tolerance for digitalis (17) . Hence, it is possible that the subsequent variability in electrocardiographic response to antidigoxin antibodies may reflect, at least in part, previously established differences in the nature of the toxic myocardial effects of digoxin in different individual animals. It is also possible that the differences in electrocardiographic response to antidigoxin antibodies may be due, at least in part, to differences in the affinities of these antibodies for digoxin. Differences in average intrinsic association constants, as much as 14-fold (17 X 109 vs. 1.2 X 109) have been reported between the antidigoxin antibodies of two different antisera (7) ; antibodies with relatively low association constants may be less effective than high-affinity antibodies in competing with myocardial digoxin-binding sites (18) . It has long been known that antibodies to certain toxic substances, such as diphtheria toxin or tetanus toxin, are incapable of reversing the toxic effects of the corresponding antigens after these toxic substances have reached their cellular sites of action (19) . Recently, however, Pastan and his colleagues have shown that antibodies specific for insulin and thyrotrophin, respectively, are capable of reversing established cellular effects of these peptide hormones on certain target tissues (20) . Moreover, Watson and Butler have demonstrated that digoxin-specific antibodies are capable of reversing an effect of digoxin on cation transport in human erythrocytes (5) . To our knowledge, however, the current study represents the first direct demonstration that antibodies are capable of reversing a toxic cellular effect of a physiologically active substance in the intact living animal. This observation suggests that antibodies may also be of value in reversing the cellular effects of other physiologically active substances.
Finally, the ability of digoxin-specific antibodies to reverse severe, potentially lethal, digoxen intoxication in the dog suggests that these antibodies may eventually be of use in severe, life-threatening digoxin intoxication in man.
